




RealRate

PHARMACEUTICAL 2017

Juniper Pharmaceuticals INC
Rank 82 of 308



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Juniper Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Juniper Pharmaceuticals INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 90% points. The greatest weakness of Juniper Pharmaceuticals INC is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 40% points.

The company's Economic Capital Ratio, given in the ranking table, is 333%, being 88% points above the market average of 245%.

Input Variable	Value in 1000 USD
Assets, Current	34,727
Cost of Goods Sold	24,293
Intangible Assets	9,311
Liabilities, Current	14,992
Liabilities, Non-Current	0
Other Assets	167
Other Compr. Net Income	-3,866
Other Expenses	1,350
Other Liabilities	2,259
Other Net Income	763
Other Revenues	54,573
Property and Equipment	13,366
Research and Development	9,676
Selling, General and Administrative Expense	14,066

Output Variable	Value in 1000 USD
Assets	57,571
Liabilities	17,251
Expenses	49,385
Revenues	54,573
Stockholders Equity	40,320
Net Income	5,951
Comprehensive Net Income	4,018
BaseVar	91,704
ECR before LimitedLiability	246%
Economic Capital Ratio	333%